Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pituitary ACTH Hypersecretion 2Ovarian Neoplasms 2Hypertension 2Fallopian Tube Neoplasms 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2Adrenocortical Carcinoma 2Adrenal Cortex Neoplasms 2ACTH Syndrome, Ectopic 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adenocarcinoma 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × relacorilant × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡